PMC:7408073 / 98067-98738 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T512","span":{"begin":379,"end":384},"obj":"Body_part"},{"id":"T513","span":{"begin":528,"end":536},"obj":"Body_part"}],"attributes":[{"id":"A512","pred":"fma_id","subj":"T512","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A513","pred":"fma_id","subj":"T513","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Briefly, one of the best candidates to treat COVID-19 patients, but not to prevent viral entry, is the small synthetic molecule MLN-4760 (specific ACE2 inhibitor, also known as C16, GL1001 or ORE1001, [113]) for the following reasons:(1) It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3437","span":{"begin":272,"end":276},"obj":"Gene"},{"id":"3438","span":{"begin":418,"end":422},"obj":"Gene"},{"id":"3439","span":{"begin":508,"end":512},"obj":"Gene"},{"id":"3440","span":{"begin":590,"end":594},"obj":"Gene"},{"id":"3441","span":{"begin":615,"end":619},"obj":"Gene"},{"id":"3442","span":{"begin":522,"end":527},"obj":"Gene"},{"id":"3443","span":{"begin":397,"end":405},"obj":"Species"},{"id":"3444","span":{"begin":412,"end":417},"obj":"Species"},{"id":"3445","span":{"begin":631,"end":641},"obj":"Species"},{"id":"3446","span":{"begin":345,"end":356},"obj":"Disease"},{"id":"3447","span":{"begin":388,"end":396},"obj":"Disease"},{"id":"3504","span":{"begin":147,"end":151},"obj":"Gene"},{"id":"3505","span":{"begin":128,"end":131},"obj":"Gene"},{"id":"3506","span":{"begin":54,"end":62},"obj":"Species"},{"id":"3507","span":{"begin":45,"end":53},"obj":"Disease"}],"attributes":[{"id":"A3437","pred":"tao:has_database_id","subj":"3437","obj":"Gene:59272"},{"id":"A3438","pred":"tao:has_database_id","subj":"3438","obj":"Gene:59272"},{"id":"A3439","pred":"tao:has_database_id","subj":"3439","obj":"Gene:59272"},{"id":"A3440","pred":"tao:has_database_id","subj":"3440","obj":"Gene:59272"},{"id":"A3441","pred":"tao:has_database_id","subj":"3441","obj":"Gene:59272"},{"id":"A3442","pred":"tao:has_database_id","subj":"3442","obj":"Gene:43740568"},{"id":"A3443","pred":"tao:has_database_id","subj":"3443","obj":"Tax:9606"},{"id":"A3444","pred":"tao:has_database_id","subj":"3444","obj":"Tax:9606"},{"id":"A3445","pred":"tao:has_database_id","subj":"3445","obj":"Tax:2697049"},{"id":"A3446","pred":"tao:has_database_id","subj":"3446","obj":"MESH:D006935"},{"id":"A3447","pred":"tao:has_database_id","subj":"3447","obj":"MESH:C000657245"},{"id":"A3504","pred":"tao:has_database_id","subj":"3504","obj":"Gene:59272"},{"id":"A3505","pred":"tao:has_database_id","subj":"3505","obj":"Gene:4295"},{"id":"A3506","pred":"tao:has_database_id","subj":"3506","obj":"Tax:9606"},{"id":"A3507","pred":"tao:has_database_id","subj":"3507","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Briefly, one of the best candidates to treat COVID-19 patients, but not to prevent viral entry, is the small synthetic molecule MLN-4760 (specific ACE2 inhibitor, also known as C16, GL1001 or ORE1001, [113]) for the following reasons:(1) It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T548","span":{"begin":45,"end":53},"obj":"Disease"},{"id":"T549","span":{"begin":388,"end":396},"obj":"Disease"},{"id":"T550","span":{"begin":631,"end":639},"obj":"Disease"},{"id":"T551","span":{"begin":631,"end":635},"obj":"Disease"}],"attributes":[{"id":"A548","pred":"mondo_id","subj":"T548","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A549","pred":"mondo_id","subj":"T549","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A550","pred":"mondo_id","subj":"T550","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A551","pred":"mondo_id","subj":"T551","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Briefly, one of the best candidates to treat COVID-19 patients, but not to prevent viral entry, is the small synthetic molecule MLN-4760 (specific ACE2 inhibitor, also known as C16, GL1001 or ORE1001, [113]) for the following reasons:(1) It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1199","span":{"begin":177,"end":180},"obj":"http://purl.obolibrary.org/obo/CLO_0002096"},{"id":"T1200","span":{"begin":241,"end":244},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T1201","span":{"begin":287,"end":295},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1202","span":{"begin":379,"end":384},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T1203","span":{"begin":412,"end":417},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T1204","span":{"begin":423,"end":431},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1205","span":{"begin":595,"end":603},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1206","span":{"begin":658,"end":660},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"}],"text":"Briefly, one of the best candidates to treat COVID-19 patients, but not to prevent viral entry, is the small synthetic molecule MLN-4760 (specific ACE2 inhibitor, also known as C16, GL1001 or ORE1001, [113]) for the following reasons:(1) It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T445","span":{"begin":119,"end":127},"obj":"Chemical"},{"id":"T21827","span":{"begin":147,"end":161},"obj":"Chemical"},{"id":"T447","span":{"begin":152,"end":161},"obj":"Chemical"},{"id":"T82941","span":{"begin":177,"end":180},"obj":"Chemical"},{"id":"T449","span":{"begin":528,"end":536},"obj":"Chemical"}],"attributes":[{"id":"A8354","pred":"chebi_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A59253","pred":"chebi_id","subj":"T21827","obj":"http://purl.obolibrary.org/obo/CHEBI_147289"},{"id":"A21399","pred":"chebi_id","subj":"T447","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A7128","pred":"chebi_id","subj":"T82941","obj":"http://purl.obolibrary.org/obo/CHEBI_15756"},{"id":"A94230","pred":"chebi_id","subj":"T449","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Briefly, one of the best candidates to treat COVID-19 patients, but not to prevent viral entry, is the small synthetic molecule MLN-4760 (specific ACE2 inhibitor, also known as C16, GL1001 or ORE1001, [113]) for the following reasons:(1) It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"LitCovid-sentences","denotations":[{"id":"T477","span":{"begin":0,"end":671},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Briefly, one of the best candidates to treat COVID-19 patients, but not to prevent viral entry, is the small synthetic molecule MLN-4760 (specific ACE2 inhibitor, also known as C16, GL1001 or ORE1001, [113]) for the following reasons:(1) It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T161","span":{"begin":345,"end":356},"obj":"Phenotype"}],"attributes":[{"id":"A161","pred":"hp_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/HP_0012416"}],"text":"Briefly, one of the best candidates to treat COVID-19 patients, but not to prevent viral entry, is the small synthetic molecule MLN-4760 (specific ACE2 inhibitor, also known as C16, GL1001 or ORE1001, [113]) for the following reasons:(1) It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"2_test","denotations":[{"id":"32708755-12358520-20679021","span":{"begin":202,"end":205},"obj":"12358520"},{"id":"32708755-22777933-20679022","span":{"begin":328,"end":331},"obj":"22777933"},{"id":"32708755-15791205-20679023","span":{"begin":538,"end":540},"obj":"15791205"}],"text":"Briefly, one of the best candidates to treat COVID-19 patients, but not to prevent viral entry, is the small synthetic molecule MLN-4760 (specific ACE2 inhibitor, also known as C16, GL1001 or ORE1001, [113]) for the following reasons:(1) It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}